Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
CARTITUDE-2
Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 2
Accepting patients
KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- High Risk
- Phase 2
- Has results
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
Accepting patients
GCO12F CAR-T
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- CD19
- Phase 1/2
Not yet accepting
SIM0500
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Trispecific Antibody
- BCMA
- GPRC5D
- Phase 1
Accepting patients
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Accepting patients
MonumenTAL-1
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)
Learn more- Bispecific Antibody
- GPRC5D
- Phase 1
- Has results
Accepting patients
ABBV-383
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
3 hidden based on your filters. Show All